17 completed, 3 terminated, 2 recruiting, 2 unknown. 11 Phase 1, 8 Phase 2, 5 Not applicable, 4 Phase 3.
Follow Antibodies: new trials by email Literature Review of Antibodies trials Research Report on Antibodies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors ZM008 - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Zumutor Biologics Inc. | 100 | 2024-05-22 | 2026-04-02 |
| bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma bTAE-HAIC, Lenvatinib, Sintilimab - Liver Diseases, Hepatocellular Carcinoma | Not applicable | Unknown | Sun Yat-sen University | 30 | 2024-05-20 | 2024-08-09 |
| bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC bTAE-HAIC, Lenvatinib, Camrelizumab - Liver Diseases, Hepatocellular Carcinoma | Not applicable | Unknown | Sun Yat-sen University | 40 | 2024-05-20 | 2024-09-23 |
| Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain Injection of humanized nerve growth factor (NGF) antibody - Cancer Pain | Phase 1 / Phase 2 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 132 | 2024-03-27 | 2025-06-06 |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) PF-07225570, sasanlimab - Bladder Cancer | Phase 1 | Withdrawn | Pfizer | 2022-03-24 | 2023-03-08 | |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab - Carcinoma, Hepatocellular, Liver Neoplasms | Not applicable | Completed | Sun Yat-sen University | 30 | 2021-01-01 | 2024-03-06 |
| Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma Nivolumab, Ch14.18/CHO - Neuroblastoma | Phase 1 | Active not recruiting | University Hospital Southampton NHS Foundation Trust | 44 | 2018-05-24 | 2026-04-28 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 144 | 2017-12-22 | 2025-11-10 |
| Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis BMS-986184, Placebo matching BMS-986184 - Healthy Volunteers, Ulcerative Colitis | Phase 1 | Terminated | Bristol-Myers Squibb | 7 | 2016-09-14 | 2017-10-20 |
| Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC Pembrolizumab, Cetuximab, Radiotherapy - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 133 | 2016-05-18 | 2023-02-28 |
| A Study of Atezolizumab in Advanced Solid Tumors Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody - Tumors | Phase 2 | Completed | Hoffmann-La Roche | 474 | 2015-07-16 | 2021-06-04 |
| A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel - Squamous Non-Small Cell Lung Cancer | Phase 3 | Completed | Hoffmann-La Roche | 1021 | 2015-06-11 | 2022-03-21 |
| A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody - Neoplasms | Phase 1 | Completed | Genentech, Inc. | 610 | 2015-04-24 | 2022-04-01 |
| Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody - Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors | Phase 1 | Completed | Baxalta now part of Shire | 68 | 2012-06-14 | 2021-05-05 |
| Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody - Systemic Lupus Erythematosus | Phase 1 | Terminated | Baxalta now part of Shire | 4 | 2011-11-28 | 2021-05-05 |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 73 | 2010-08-13 | 2023-07-19 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
| Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Belimumab - Sjögren's Syndrome | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2010-03-01 | 2012-07-03 |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS - Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | St. Jude Children's Research Hospital | 17 | 2005-08-01 | 2009-01-29 |
| Stem Cell Transplantation for Children Affected With Osteopetrosis Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies - Osteopetrosis | Not applicable | Terminated | St. Jude Children's Research Hospital | 15 | 2004-07-01 | 2017-05-30 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myeloid, Acute (5) · Hemoglobinuria, Paroxysmal (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myelomonocytic, Juvenile (4) · Lymphoma, Non-Hodgkin (4) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (2) · Hodgkin Disease (2) · Leukemia (2) · Liver Diseases (2) · Melanoma (2) · Neoplasms (2) · Neuroblastoma (2)
St. Jude Children's Research Hospital (6) · Hoffmann-La Roche (3) · Sun Yat-sen University (3) · Baxalta now part of Shire (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Children's Oncology Group (1) · Genentech, Inc. (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Memorial Sloan Kettering Cancer Center (1) · Pfizer (1) · Shenyang Sunshine Pharmaceutical Co., LTD. (1) · University Hospital Southampton NHS Foundation Trust (1) · Zumutor Biologics Inc. (1)
United States (19) · Australia (5) · Canada (5) · France (5) · China (4) · Germany (3) · Spain (3) · Austria (2) · Belgium (2) · Brazil (2) · Israel (2) · Italy (2) · Mexico (2) · Netherlands (2) · Poland (2)
Gregory Hale, M.D. (3) · Zhimei Hunag, MD (2) · Brandon Triplett, MD (1) · Gregory A. Hale, M.D. (1) · Jinhua Huang, Profession (1) · Jinhua Huang, Professor (1) · Juliet Gray (1) · Jyotsna Fuloria (1) · Kangshun Zhu, MD (1) · Kimberly A Kasow, DO (1) · Maloy Ghosh, PhD (1)
PMID 11118469, PMID 12091876, PMID 12218188, PMID 15269160, PMID 1576319, PMID 15869455, PMID 15950727, PMID 16382236, PMID 1638557, PMID 1643631, PMID 17369569, PMID 19047298, PMID 19171714, PMID 19304016, PMID 19626208, PMID 19638464, PMID 20570856, PMID 20879881, PMID 21074057, PMID 21149662, PMID 21298742, PMID 21798350, PMID 22186141, PMID 22658127, PMID 22658128, PMID 22700000, PMID 22844125, PMID 23649004, PMID 23661160, PMID 23724867, PMID 24145345, PMID 24333097, PMID 24848257, PMID 2514231, PMID 25604432, PMID 26320062, PMID 26336930, PMID 26639390, PMID 26785755, PMID 29376112, PMID 3094017, PMID 32207164, PMID 35305400, PMID 35511917, PMID 36450385, PMID 7718335, PMID 8270976, PMID 8635190, PMID 8811495, PMID 9217046
2015 (2), 2016 (2), 2014 (1), 2017 (1), U10CA013539 (1), U10CA098543 (1), U10CA180886 (1)